OVERALL SURVIVAL EVALUATION OF PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY BY ESTIMATING FLUCTUANT PATTERNS OF METABOLIC FACTOR SERUM LEVELS-Reference-Cited by-同舟云学术

OVERALL SURVIVAL EVALUATION OF PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY BY ESTIMATING FLUCTUANT PATTERNS OF METABOLIC FACTOR SERUM LEVELS

Published:2022-01-20 Issue:1 Volume:113 Page:1-11
ISSN:0021-5287
Container-title:The Japanese Journal of Urology
language:en
Short-container-title:Jpn. j. urol

Author:

Shimabukuro Tomoyuki¹,Ohmi Chietaka¹,Baba Chieko²,Shiraishi Koji²

Affiliation:

1. Department of Urology, Ube-kosan Central Hospital Corp

2. Department of Urology, Graduate School of Medicine, Yamaguchi University

Publisher

Japanese Urological Association

Subject

Urology

Link

https://www.jstage.jst.go.jp/article/jpnjurol/113/1/113_1/_pdf

Reference25 articles.

1. 1) Matsuyama H, Shimabukuro T, Hara I, Kohjimoto Y, Suzuki K, Koike H, Uemura H, Hayashi T, Ueno M, Kodaira K, Tomita Y, Sakurai T and Shimizu N: Combination of hemoglobin, alkaline phosphate, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int. J. Clin. Oncol., 19, 946-954, 2014.

2. 2) 島袋智之, 大見千英高, 長光涼子, 白石晃司, 松山豪泰: 去勢抵抗性前立腺癌診断時の転移巣の有無が生存予後に与える影響. 西日泌尿, 83, 14-21, 2021.

3. 3) 島袋智之, 大見千英高, 長光涼子, 白石晃司, 松山豪泰: 全臨床病期前立腺癌を対象にした予後予測のための臨床リスク分類の新提案. 西日泌尿, 84, 56-65, 2021.

4. 4) Rehman Y and Rosenberg JE: Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des. Devel. Ther., 6, 13-18, 2012.

5. 5) Schalken J and Fitzpatrick JM: Enzalutamide: targeting the androgen signaling pathway in metastatic castration-resistant prostate cancer. BJU int., 117, 215-225, 2016.